Meeting
2018 ASCO Annual Meeting
Comparison of different phase II studies using sequential combinations of targeted agents for treating chronic lymphocytic leukemia.
Authors
Von Tresckow Julia
Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University of Cologne, Cologne, Germany
Von Tresckow Julia , Paula Cramer , Jasmin Bahlo , Sandra Robrecht , Othman Al-Sawaf , Petra Langerbeins , Moritz Fürstenau , Anja Engelke , Anna-Maria Fink , Kirsten Fischer , Karl A Kreuzer , Matthias Ritgen , Sebastian Boettcher , Clemens Martin Wendtner , Stephan Stilgenbauer , Barbara Eichhorst , Michael J. Hallek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Chronic Lymphocytic Leukemia (CLL) and Hairy Cell
Clinical Trial Registration Number
NCT02689141, NCT02401503 and NCT02345863
Citation
J Clin Oncol 36, 2018 (suppl; abstr 7513)
DOI
10.1200/JCO.2018.36.15_suppl.7513
Abstract #
7513
Poster Bd #
150
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Four-year follow-up from a phase 2 study of obinutuzumab, ibrutinib, and venetoclax in CLL.
First Author: Kerry Anne Rogers
Poster
2023 ASCO Annual Meeting
Fixed-duration ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): 4-y follow-up from the FD cohort of the phase 2 CAPTIVATE study.
First Author: Paul M. Barr
Poster
2020 ASCO Virtual Scientific Program
Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial.
First Author: Othman Al-Sawaf
Poster
2018 ASCO Quality Care Symposium
Impact of novel chronic lymphocytic leukemia drugs on public spending.
First Author: Elena Mow